Eloctate

Groundbreaking gene therapies in store for hemophiliaTreatment failures can result in a spectrum of problems for patients with hemophilia. Here’s some guidance on choosing the right therapy.
FDA drug approvals-July 2014FDA drug approvals, priority review, breakthrough designation, fast-track designations, orphan drug designations, first-time generic approval
FDA approves first hemophilia A drug to extend interval between prophylactic infusions in adults and childrenFDA has approved Antihemophilic Factor (Recombinant), Fc Fusion Protein (Eloctate, Biogen Idec) for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with hemophilia A.